The Global Viral Vector Manufacturing Market was valued at USD 0.9 billion in 2022 and is anticipated to reach USD 3.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 20.3% from 2024 to 2031. This growth is being driven by a rising demand for gene therapies and cell-based treatments, increased investments in biopharmaceutical research and development, and expanding uses of viral vectors in vaccine development. Advancements in vector engineering and a growing number of clinical trials are also contributing to this market expansion.
Key developments in the industry include WuXi Biologics’ expansion of viral vector production in Philadelphia to meet rising gene therapy demands, and Thermo Fisher Scientific’s launch of an upgraded purification platform in California. In Asia, significant investments include China’s allocation of USD 4.17 billion for biomanufacturing expansions and Japan’s updated guidelines for AAV vectors, prompting upgrades for commercial production in local facilities.
The market is segmented by type, with Adeno-Associated Viral (AAV) vectors holding a dominant share of 40% in 2025, primarily used for gene therapies. Cancer accounts for the largest disease segment at 35% market share, driven by targeted gene delivery and oncolytic virotherapies.
- Why it matters: The growth in the viral vector manufacturing market indicates increased opportunities for businesses in biotechnology and offers insights into emerging therapies and vaccine development.
- The latest: WuXi Biologics is boosting its production capacity with new facilities in multiple regions to meet surging gene therapy needs.
Source: https://www.openpr.com/news/4306680/viral-vector-manufacturing-market-set-for-strong-growth-to-usd
Source: https://www.openpr.com/news/4306680/viral-vector-manufacturing-market-set-for-strong-growth-to-usd